289 related articles for article (PubMed ID: 37001610)
1. Downregulation of striatal Ca
Caulfield ME; Vander Werp MJ; Stancati JA; Collier TJ; Sortwell CE; Sandoval IM; Manfredsson FP; Steece-Collier K
Neurobiol Dis; 2023 Jun; 181():106111. PubMed ID: 37001610
[TBL] [Abstract][Full Text] [Related]
2. Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Steece-Collier K; Stancati JA; Collier NJ; Sandoval IM; Mercado NM; Sortwell CE; Collier TJ; Manfredsson FP
Mov Disord; 2019 May; 34(5):697-707. PubMed ID: 31002755
[TBL] [Abstract][Full Text] [Related]
3. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
4. Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.
Steece-Collier K; Collier TJ; Lipton JW; Stancati JA; Winn ME; Cole-Strauss A; Sellnow R; Conti MM; Mercado NM; Nillni EA; Sortwell CE; Manfredsson FP; Bishop C
Exp Neurol; 2020 Aug; 330():113327. PubMed ID: 32387398
[TBL] [Abstract][Full Text] [Related]
5. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
[TBL] [Abstract][Full Text] [Related]
6. Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Tohge R; Kaneko S; Morise S; Oki M; Takenouchi N; Murakami A; Nakamura M; Kusaka H; Yakushiji Y
Neuropharmacology; 2021 Oct; 198():108771. PubMed ID: 34474045
[TBL] [Abstract][Full Text] [Related]
7. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
8. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
9. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
[TBL] [Abstract][Full Text] [Related]
10. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Wang Y; Zhang GJ; Sun YN; Yao L; Wang HS; Du CX; Zhang L; Liu J
Behav Brain Res; 2018 Jul; 347():175-183. PubMed ID: 29551735
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and cellular dopamine D
Lanza K; Meadows SM; Chambers NE; Nuss E; Deak MM; Ferré S; Bishop C
Neuropharmacology; 2018 Aug; 138():304-314. PubMed ID: 29936243
[TBL] [Abstract][Full Text] [Related]
12. Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Figge DA; Eskow Jaunarajs KL; Standaert DG
J Neurosci; 2016 Jun; 36(24):6514-24. PubMed ID: 27307239
[TBL] [Abstract][Full Text] [Related]
13. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
14. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Tronci E; Napolitano F; Muñoz A; Fidalgo C; Rossi F; Björklund A; Usiello A; Carta M
Exp Neurol; 2017 Nov; 297():73-81. PubMed ID: 28757258
[TBL] [Abstract][Full Text] [Related]
15. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z
Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117
[TBL] [Abstract][Full Text] [Related]
16. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
[TBL] [Abstract][Full Text] [Related]
17. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
19. The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinson's Disease.
Caulfield ME; Manfredsson FP; Steece-Collier K
Handb Exp Pharmacol; 2023; 279():107-137. PubMed ID: 36592226
[TBL] [Abstract][Full Text] [Related]
20. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
